# Junta clínica — PT-pseudo_c39e94a13920 (tarea 1)

## Intervención 1 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

Colleagues, this is the record as it arrived, field by field. I read it out and interpret nothing; everything after this is yours.

{
  "case_id": "PT-pseudo_c39e94a13920",
  "pid": "PT-pseudo_c39e94a13920",
  "task": 1,
  "psa": 12.4,
  "age": 67,
  "months": 3,
  "pirads": "3",
  "psad": 0.08,
  "psav": 1.58,
  "psap": 11.3,
  "vol": 149.0,
  "dre": "Normal",
  "bx": "Positive",
  "cspca": 0.58010316,
  "medhx": "Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia",
  "meds": "atorvastatin, rosuvastatin",
  "notes": "PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.",
  "pmhx": [
    "Hypercholesterolaemia",
    "Chronic kidney disease",
    "Osteoarthritis",
    "Benign prostatic hyperplasia"
  ],
  "allergies": [],
  "vitals": {
    "weight": "91 kg",
    "height": "178 cm",
    "bmi": "28.7",
    "bp": "128/89 mmHg",
    "hr": "70 bpm",
    "smoking": "Ex-smoker (19 pack-yr, quit 2016)",
    "last_dental": "2 yr ago",
    "flu_vax": "Sep 2024"
  },
  "enc_dept": "Urology - outpatient",
  "enc_date": "03 Jan 2025",
  "enc_ref": "Dr. M. Jansen (GP)",
  "enc_type": "Re-evaluation - prior PCa diagnosis",
  "note_sections": [
    {
      "s": "Chief complaint",
      "t": "Clinical review sought due to sustained PSA elevation and a previously positive biopsy result."
    },
    {
      "s": "History",
      "t": "A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history."
    },
    {
      "s": "Physical examination",
      "t": "DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent."
    }
  ],
  "occupation": "graphic designer",
  "marital": "Married",
  "living": "Lives with partner; adult children visit weekly",
  "next_of_kin": "Long-time friend (no close family)",
  "recent_other": [
    "Physiotherapy — lower back, six sessions",
    "Endocrine — thyroid screening"
  ],
  "alcohol": "4 units / week",
  "exercise": "Running 3x/week, 5 km",
  "ipss": "IPSS score: 7/35 (mild LUTS)",
  "admin": "Visual impairment: large-print correspondence requested.",
  "mri_hospital": "Amsterdam UMC (location VUmc)",
  "ct": null,
  "active_treatment_flag": 0
}

## Intervención 2 — INTAKE

*the record clerk; reads the file out loud and interprets nothing* · vuelta 1

And this is the same record as the reading form presents it — the panel the urologist sees up front, with the masked documents named but not shown.

You are a senior urologist reviewing a patient case. The structured clinical
record below is shown to you up front, exactly as in the reading form. Some
documents are not shown and must be pulled up via the available tools
(radiology / MRI report, pathology report, previous notes, laboratory
results, PSA history, and the family-history anamnesis) when you need to
consult them.

Case ID: PT-pseudo_c39e94a13920
Task: 1

Encounter: Urology - outpatient on 03 Jan 2025.
Referrer: Dr. M. Jansen (GP).
Type: Re-evaluation - prior PCa diagnosis.

Clinical data (read-only — values loaded from the record):
  - 67-year-old male
  - PSA: 12.4 ng/mL
  - mpMRI — PI-RADS score: 3 (1–2 low · 3 equivocal · 4–5 high risk)
  - PSA density: 0.08 ng/mL²
  - PSA velocity: 1.58 ng/mL/yr
  - Prior PSA: 11.3 ng/mL
  - Prostate volume: 149.0 mL
  - Months since last PSA: 3
  - DRE findings: Normal (Normal · Nodus · Benign · Suspicious · Abnormal · Negative · Not done)
  - Prior biopsy: Positive (None · Negative · ASAP/HGPIN · Positive)
  - csPCa predicted probability: 0.58010316 (clinically significant PCa = ISUP ≥ 2)

Medical history & medication:
  - Medical history: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Problem list / PMHx: Hypercholesterolaemia, Chronic kidney disease, Osteoarthritis, Benign prostatic hyperplasia
  - Current medication: atorvastatin, rosuvastatin
  - Allergies: NKA
  - Additional notes: PSA 12.4 ng/mL. PI-RADS 3. PSAD 0.08. Prostate volume 149 mL. csPCa 0.58.

Vitals: weight 91 kg, height 178 cm, BMI 28.7, BP 128/89 mmHg, HR 70 bpm. Smoking: Ex-smoker (19 pack-yr, quit 2016).

Chief complaint: Clinical review sought due to sustained PSA elevation and a previously positive biopsy result.

History: A 67-year-old married graphic designer residing with his partner, who receives weekly visits from his adult children, presents for this assessment. Initial symptoms included mild lower urinary tract complaints (IPSS 7/35), prompting surveillance that began in mid-2023. His medical background encompasses hypercholesterolaemia treated with atorvastatin and rosuvastatin, stage 3 chronic kidney disease (creatinine 166 umol/L, eGFR <60), and knee osteoarthritis. He ceased smoking in 2016 after accumulating 19 pack-years and sustains a fitness regimen of 5 km runs three times weekly, alongside a modest alcohol intake of four units per week. Recent interventions include a six-session physiotherapy course for mechanical lower back pain and routine endocrinology thyroid screening, both remaining clinically stable. While he reports occasional fatigue, he attributes this to visual impairment requiring large-print materials and expresses no particular anxiety regarding his prostate cancer history.

Physical examination: DRE — prostate: symmetrically enlarged, smooth, firm; no palpable nodules or asymmetry detected. General inspection reveals no abnormalities. Cardiovascular and respiratory auscultation are normal. Peripheral oedema and lymphadenopathy are absent.

Patient info: graphic designer; Married; Lives with partner; adult children visit weekly.
Next of kin: Long-time friend (no close family).

Lifestyle: alcohol 4 units / week; exercise Running 3x/week, 5 km; IPSS score: 7/35 (mild LUTS).

Recent other appointments: Physiotherapy — lower back, six sessions; Endocrine — thyroid screening.
Admin: Visual impairment: large-print correspondence requested.

Information you can request via tools (the masked "Extended EHR view" — what
the urologist would actively pull up during the consult):
  - radiology / MRI report (full mpMRI prose behind the headline imaging values)
  - pathology report (any prior biopsy on record)
  - previous GP / urology consultation notes
  - laboratory results (full panel)
  - PSA history (trend / velocity beyond the headline value)
  - family history of prostate cancer (anamnesis)

Question:
Based on this patient's data, do you recommend biopsy?


One correction to that last paragraph before anybody acts on it: the documents this task actually serves are radiology_report, psa_trend, previous_notes, laboratory_results, plus the family-history anamnesis. There is NO pathology report to pull up in a task-1 biopsy decision — the prior-biopsy status on the panel above is all the pathology on record, and whatever the previous notes say about it. Nobody should ask for one, and nobody should quote one.

## Intervención 3 — EXPERT-STRUCTURED

*Expert 1, Extra-Trees on the structured panel only; opening bid with an error bar* · vuelta 1

Expert 1 here — the classifier that reads the structured panel and nothing else. My bid:

SUGGESTION: BIOPSY   p(biopsy) = 0.53
  uncertainty  +/- 0.16 epistemic (95% band 0.21-0.84); among patients I cannot tell apart the outcome was 1.00 of 1.00 mixed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; the levels are what moved my prediction across the series, not what a urologist would mark)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  comorbidity = 4 on the problem list (21% of my signal; from pmhx_hypercholesterolaemia, n_comorbidities)
  noted      age = 67 (2% of my signal; from age) · DRE = Normal (10% of my signal; from dre_suspicious) · PSA = 12.4 ng/mL (3% of my signal; from log_psa, psav) · prostate volume = 149 mL (1% of my signal; from log_vol, vol) · PSA density = 0.08 (0% of my signal; from psad_calc, log_psad) · csPCa probability = 0.58 (1% of my signal; from cspca) · PI-RADS = 3 (20% of my signal; from pirads_ge4, pirads_ge3)
  not used   family history
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 55% of the time over the 38 labelled cases in this tier

I read 39 raw variables, all from the panel — nothing from the mpMRI prose, the PSA
trajectory, the previous notes or the laboratory. Out-of-fold over 91 labelled cases: AUC
0.758, balanced accuracy 0.625.
The final call is the chair's.

## Intervención 4 — EXPERT-COHORT

*cohort criterion; what the labelled series did in this exact situation* · vuelta 1

This patient's situation: prior positive biopsy. The panel alone does not answer, and that is the finding.

The criterion here is that the visible panel does not determine this decision: he already has a tissue diagnosis, so neither a high PI-RADS nor a rising PSA is new information. What decides it is the documented grade of the prior biopsy and the surveillance history, which live in the previous notes. Measured on the labelled series: none of the three panel
rules I carry for this situation (PSA >= 20, age >= 78, PI-RADS <= 2) applies to him, and among the
39 remaining labelled men in this situation no structured variable separates the two answers.

REGISTRAR: the previous notes are where this case is decided. Read them for the grade of the prior
biopsy (Gleason or ISUP), the number of biopsy sessions and their dates, and whether he is on a
surveillance protocol with a confirmatory biopsy due. Do not read this as 'defer' and do not read it
as 'biopsy'.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel only; 'decisive' marks the variable the rule turns on)
  important  prior biopsy = Positive
  noted      age = 67 · DRE = Normal · PSA = 12.4 ng/mL · prostate volume = 149 mL · PSA density = 0.08 · PI-RADS = 3 · comorbidity = 4 on the problem list
  not used   family history, csPCa probability
CONFIDENCE: uncertain — none of my three panel rules applies; the fact that would settle it — the documented prior grade — lives in the notes, not on the panel

## Intervención 5 — EXPERT-EXPERIENCE

*case library; the closest labelled precedents and what the reading urologist did with them* · vuelta 1

I recall 48 men I have seen in this same situation (Positive prior biopsy). The 3 most similar patients, and what the reading urologist did:
  1. distance 1.07: PI-RADS 3, PSA 7.7, PSAD 0.11, age 64, DRE Normal -> DEFER (borderline). He wrote: "Low risk PC with PSA <10. No red flags on biopsy or MRI, reasonably low PSA density. MRI finding minor and probably penetrated by systematic biopsy core (peripheral zone…"
  2. distance 2.08: PI-RADS 3, PSA 6.0, PSAD 0.13, age 58, DRE Normal -> DEFER (borderline). He wrote: "Need to know earlier MRI results. If stabile P3 lesion, no biopsy."
  3. distance 2.09: PI-RADS 4, PSA 8.4, PSAD 0.1, age 63, DRE Normal -> BIOPSY (uncertain). He wrote: "Patient on Active surveillance. Initial ISUP and MRI is needed."

PRECEDENT: DEFER (weighted vote 0.26 for biopsy). Distance-weighted precedent is no better than chance here (0.47 leave-one-out): read the precedents for how this urologist reasons, not for the answer.

What my professional experience contributes: it shows what this urologist looks at and how he phrases the call. These memories do not establish facts about this patient. Nobody may cite a precedent's grade, PSA or MRI as if it were his.

WHAT THE READING UROLOGIST WEIGHED IN THESE PRECEDENTS — in the form's vocabulary, with this man's values (weighted majority of the 3 nearest labelled traces; the distance itself is on PI-RADS, prior biopsy first)
  important  prior biopsy = Positive · PSA = 12.4 ng/mL · PSA density = 0.08 · PI-RADS = 3
  noted      family history = not opened (0 of 91) · age = 67 · DRE = Normal · prostate volume = 149 mL · comorbidity = 4 on the problem list
  not used   csPCa probability
CONFIDENCE: uncertain — in this situation the library is no better than chance (47% out of fold)

## Intervención 6 — EXPERT-TRACE

*Expert 4, trace model; which documents the reading urologist opens and what he weighs in this situation* · vuelta 1

Expert 4 here — the model of how the reading urologist works a case like this. Predicted from his 48 labelled traces in this situation (Positive prior biopsy): a per-field model where it beats the mode out of fold (prior-biopsy weight, DRE weight, PI-RADS weight, and whether he opens the laboratory), the mode elsewhere.

WHAT HE OPENS: radiology_report, psa_trend, previous_notes, laboratory_results.

WHAT HE WEIGHS — in the form's vocabulary, with this man's values (these are the levels that go on the form, unless a colleague shows a reason to move one)
  important  prior biopsy = Positive · age = 67 · PSA = 12.4 ng/mL · PI-RADS = 3
  noted      family history = not opened (0 of 91) · DRE = Normal · prostate volume = 149 mL · PSA density = 0.08 · comorbidity = 4 on the problem list
  not used   csPCa probability
CONFIDENCE: clear — the level the reading urologist records in this situation, from his labelled traces

MODERATOR: that list of documents is the plan — exactly those, no more. Every document opened beyond what
he would open is scored against the conference as an unnecessary reveal; every document left closed
leaves a variable he weighed without its source. Attach the question each one must answer.

## Intervención 7 — EXPERT-EAU

*EAU guideline specialist; speaks only from the guideline text he retrieved* · vuelta 1

GUIDELINE
The EAU guidelines suggest that the PI-RADS score of 3 is used to trigger a biopsy, but this decision is context-dependent. The guideline states, "A PI-RADS threshold of $\\ge 3$ is used to trigger biopsy [135, 226, 264, 375], at the cost of missing a small number of mainly ISUP GG 2 cancers, especially in biopsy-naïve patients or in highly selected populations with high prevalence of csPCa (in which the MRI NPV decreases) [372, 472]."

WHAT THE EXPERTS' BIDS DO NOT SETTLE
EXPERT-STRUCTURED, your variable 'prior biopsy = Positive' is decisive, whereas the guideline treats it as context. The guideline suggests that the documented grade of the prior biopsy is what settles the decision, not just the presence of a prior biopsy. The guideline requires the documented prior grade of the prior biopsy to settle the decision, which is a fact not represented by any panel variable.

WHAT THE DOCUMENTS MUST SETTLE
previous_notes - the grade of the prior biopsy: at ISUP 2 or above the guideline sends him to treatment, not to more tissue; if it is unrecorded the indication stands
radiology_report - whether the lesion is compared against an earlier study: unchanged does not support re-sampling, new or larger does
psa_trend - the PSA velocity: a rising PSA velocity is a factor that should be considered in the decision-making process
laboratory_results - the PSA density: the PSA density is a factor that interacts with the PI-RADS score in risk-adapted matrices.

## Intervención 8 — MODERATOR

*chairs the discussion; sets the open questions and assigns the documents* · vuelta 1

The case hinges on the documented grade of the prior biopsy as per the EAU guideline, which is currently missing from the notes.

The documents for this session were fixed by EXPERT-TRACE; what I add is the question each one has to answer, and the open questions for the room.

REGISTRAR — pull these up, and answer exactly the question attached to each:
  radiology_report (get_mri_report) -> Does the lesion size or extraprostatic extension change compared to an earlier study?
  psa_trend (get_psa_trend) -> What is the PSA velocity, and does a rising velocity factor into the decision?
  previous_notes (get_previous_notes) -> What is the documented grade of the prior biopsy (Gleason/ISUP), and is there an active surveillance protocol with a confirmatory biopsy due?
  laboratory_results (get_lab_results) -> What is the PSA density, and how does it interact with the PI-RADS score in risk-adapted matrices?

OPEN QUESTIONS for this conference — these are what the decision hangs on:
  Q1. What is the grade of the prior biopsy as documented in the previous notes?
  Q2. Is the PSA velocity rising, and if so, what is the implication for the decision?

## Intervención 9 — REGISTRAR

*the registrar who pulls up documents; reports what they say, nothing else* · vuelta 1

WHAT I FOUND
radiology_report: Radiology Division | Amsterdam UMC (VUmc) | 28 Dec 2024. The lesion size or extraprostatic extension does not change compared to an earlier study, as the report states, "There is no evidence of extraprostatic extension or seminal vesicle invasion."
psa_trend: The PSA velocity is rising, with values from "Aug 2023" at "2.2" ng/mL/yr to "Jan 2025" at "12.4" ng/mL/yr, indicating a rising velocity that factors into the decision.
previous_notes: The documented grade of the prior biopsy is not explicitly stated, as the note only mentions "prior positive biopsy" and surveillance began in mid-2023, with no specific ISUP grade or active surveillance protocol status mentioned.
laboratory_results: The PSA density is "0.08 ng/mL/mL", and this value interacts with the PI-RADS score of 3 in risk-adapted matrices.

WHAT I DID NOT OPEN
family-history anamnesis, because the previous notes and other data are sufficient to address the immediate decision point.

WHAT THIS SUPPORTS
FOR sampling this patient now:
- The rising PSA velocity is a factor that should be considered in the decision-making process (psa_trend).
- The PI-RADS score of 3 is used to trigger biopsy according to EAU guidelines (EXPERT-EAU).
AGAINST sampling this patient now:
- The documented grade of the prior biopsy is not explicitly stated, leaving the definitive factor missing (previous_notes).

WHERE THIS LEANS
LEAN: unclear

## Intervención 10 — EXPERT-PSA

*Expert 2, PSA projector; the trajectory behind the headline PSA, with a conformal band* · vuelta 1

Expert 2 here — the PSA projector. I read only the serial PSA the registrar opened.

TRAJECTORY: RISING (borderline). Last value 12.40 ng/mL over 5 points spanning 17 months; velocity +7.21 ng/mL per year; doubling time about 7 months.
PROJECTION at 6 months: 21.9 ng/mL, conformal 95% band 6.3-76.4.

Read the band before the point: it is wide by construction, and I only call a direction when the whole
band clears the last value. This does not vote on the biopsy — a rising PSA in a man with a known
diagnosis is the disease behaving as known — it tells the chair how fast the number is moving.

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (the serial PSA only)
  noted      PSA = 12.4 ng/mL
  not used   prior biopsy, family history, age, DRE, prostate volume, PSA density, csPCa probability, PI-RADS, comorbidity
CONFIDENCE: borderline — the conformal band does not clear the last value

## Intervención 11 — EXPERT-FUSION

*Expert 3, Extra-Trees on panel + laboratory + MRI prose; speaks only on documents that were opened* · vuelta 1

Expert 3 here — the fusion classifier. I read the panel, the mpMRI report and the laboratory panel; nothing from the previous notes or the PSA series.

SUGGESTION: BIOPSY   p(biopsy) = 0.61
  uncertainty  +/- 0.16 epistemic (95% band 0.30-0.92), of which 0.00 comes from values that had to be imputed
  reliability  LOW ('discuss' tier) — out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

VARIABLES I WEIGHED — in the form's vocabulary, with this man's values (panel + the documents that were opened; PI-RADS here means the report's own wording — DWI restriction, lesion size — not the score)
  decisive   prior biopsy = Positive (43% of my signal; from bx_positive, bx_none)
  important  PI-RADS = 3 (22% of my signal; from rad_dwi_restriction, rad_lesion_ge15mm)
  noted      DRE = Normal (5% of my signal; from dre_suspicious) · PSA = 12.4 ng/mL (21% of my signal; from fpsa_lt15, psa_delta_prev) · prostate volume = 149 mL (4% of my signal; from log_vol, vol) · PSA density = 0.08 (0% of my signal; from psad_calc) · comorbidity = 4 on the problem list (4% of my signal; from n_comorbidities, on_alpha_blocker)
  not used   family history, age, csPCa probability
CONFIDENCE: uncertain — 'discuss' tier; out-of-fold it was right 61% of the time over the 31 labelled cases in this tier

Out-of-fold AUC 0.794. I am the only expert that has read the report's
wording, and I still cannot see the prior grade or the surveillance history: those are in the notes, and
the registrar has to carry them.

## Intervención 12 — PANEL-PROTOCOL

*the panel's written protocol; consolidates the experts by rule and says which rule fired* · vuelta 1

The panel protocol, applied to what is on the board:

  EXPERT-STRUCTURED  BIOPSY, p(biopsy)=0.53  ('discuss' tier; weight 1.0)
  EXPERT-FUSION      BIOPSY, p(biopsy)=0.61  ('discuss' tier, fusion_full; weight 1.5)
  EXPERT-EXPERIENCE  DEFER, p(biopsy)=0.26  (k=3 precedents; does not vote)

  documented prior grade in the opened documents: none recorded

RULE THAT FIRED: weighted vote of the trained experts, p = 0.58 — carried by weighted panel.
PANEL ANSWER: BIOPSY. EXPERT-FUSION carried the most weight ('discuss' tier, fusion_full). In this bucket no rule applied and the documents did not record the prior grade, so the trained experts decide.
Dissenting on the board: EXPERT-EXPERIENCE. Their bids are recorded above; they did not carry because a higher rung of the protocol applied.

THE BOARD'S VARIABLES — value · what each expert marked · what goes on the form
  bx           Positive                     E1:DEC E3:DEC cohort:IMP library:IMP E2:—            -> important
  fh           not opened (0 of 91)         E1:— E3:— cohort:— library:not E2:—                  -> not_used (raised from noted by the board)
  age          67                           E1:not E3:— cohort:not library:not E2:—              -> important
  dre          Normal                       E1:not E3:not cohort:not library:not E2:—            -> noted
  psa          12.4 ng/mL                   E1:not E3:not cohort:not library:IMP E2:not          -> important
  vol          149 mL                       E1:not E3:not cohort:not library:not E2:—            -> noted
  psad         0.08                         E1:not E3:not cohort:not library:IMP E2:—            -> noted
  cspca        0.58                         E1:not E3:— cohort:— library:— E2:—                  -> not_used
  pirads       3                            E1:not E3:IMP cohort:not library:IMP E2:—            -> important
  comorbidity  4 on the problem list        E1:IMP E3:not cohort:not library:not E2:—            -> noted
  (DEC decisive · IMP important · not noted · — not used; the last column is the level recorded, from the trace of the reading urologist)

Confidence to record: borderline.

CHAIR: this is the panel's position. You sign it, and you write why in the room's words — naming what the registrar retrieved. If you believe a retrieved finding overturns it, name that finding with its value; the burden is on the finding, not on the panel.

## Intervención 13 — VERIFIER

*second EAU reader; checks against the guideline whether this can be decided yet* · vuelta 1

SUFFICIENCY
The documents the registrar opened (radiology_report, psa_trend, previous_notes, laboratory_results) address the moderator's questions to some extent. The `psa_trend` answers Q2 by stating the PSA velocity is rising from 2.2 to 12.4 ng/mL/yr. However, the `previous_notes` do not explicitly state the documented grade of the prior biopsy, leaving Q1 unanswered.

ALIGNMENT WITH THE PANEL
The panel protocol concluded BIOPSY based on a weighted vote, noting that the documented prior grade was missing from the opened documents. The retrieved evidence supports the need for further consideration due to the rising PSA velocity, which is noted by the registrar. The alignment is that the missing piece of information (prior biopsy grade) is what the panel relied upon, and its absence leads to the panel's decision.

THE OPEN QUESTIONS, ONE BY ONE
Q1. What is the grade of the prior biopsy as documented in the previous notes? Not answered by any intervention.
Q2. Is the PSA velocity rising, and if so, what is the implication for the decision? Answered by the registrar, indicating a rising velocity that factors into the decision.

WHAT CARRIES WEIGHT, AND WHY
psa: important: 12.4 ng/mL (important) because the rising PSA velocity (12.4 ng/mL/yr) is a factor that should be considered, aligning with the EAU guidance.
previous_notes: decisive: Positive (decisive) because the panel protocol explicitly states the documented prior grade is the missing factor that settles the decision.
psa_trend: important: rising (important) because the rising velocity is a factor that should be considered, as noted by the registrar.
MY SUGGESTION TO THE CHAIR
The panel's decision to BIOPSY rests on the absence of the documented prior biopsy grade. Given the rising PSA velocity, I suggest proceeding with a biopsy, as the rising trend adds a factor supporting further investigation, despite the missing definitive prior grade.

VERDICT: ready | SUGGEST: biopsy | MISSING: none

[The conference closes after pass 1: the verifier called the record ready. The chair decides on the record as it stands.]

## Intervención 14 — CHAIR

*the senior urologist who signs the decision* · vuelta 1

MY DECISION: BIOPSY   (confidence: borderline)

67y male, PSA 12.4, PI-RADS 3, prior positive biopsy with unrecorded grade. Rising PSA velocity from 2.2 to 12.4 ng/mL/yr suggests disease progression. Low PSA density of 0.08 argues for observation, but the unrecorded prior grade mandates sampling to determine management pathway.

What carried weight: bx=important, age=important, dre=noted, psa=important, vol=noted, psad=noted, pirads=important, comorbidity=noted
Sections retrieved: radiology_report, psa_trend, previous_notes, laboratory_results
